Massive Bio Named to NYC Digital Health 100

New York, NY (February 1, 2022) – Massive Bio today announced that New York City Health Business Leaders (NYCHBL), the organization that serves as the gateway to New York’s healthcare ecosystem, has recognized the company on its NYC Digital Health 100, showcasing the most exciting and innovative health start-ups in New York.  

“We are very excited and honored to be included among many other great startups in the healthcare industry. Massive Bio has been headquartered in New York City since being founded in 2015, so being selected to this list is especially rewarding. We will continue connecting cancer patients in New York City and around the world to leading edge therapies in clinical trials” said Massive Bio Co-Founder and CEO Selin Kurnaz. 

“This year, the NYC Digital Health 100 is comprised of an incredibly diverse set of companies and leaders who are working to innovate and solve some of the most complex challenges across all facets of the healthcare ecosystem,” said Bunny Ellerin, co-founder and CEO, NYCHBL. “We are delighted to recognize these companies and celebrate and support their growth in the New York area.” 

Massive Bio’s mission of providing cancer patients with access to new therapies and clinical trials combined with an artificial intelligence (AI) powered platform can give patients new opportunities to treat their cancer. With over 18,000 actively recruiting cancer clinical trials, Massive Bio’s Clinical Trial Matching System (CTMS) provides improved outcomes for cancer patients as well as contributes to faster drug development in cancer research. 

The NYC Digital Health 100 was released in conjunction with the NYCHBL Healthcare Innovation Report 2022, an in-depth look at the data, trends and insights that define the healthcare industry in NY. In 2021, 182 companies raised an historic high of $9.0B, a 150% increase from 2020 ($3.6B) and 87% of the investments went to start-ups in areas including virtual care, patient engagement and mental health. View the full report here. 

NYC Digital Health 100 Methodology 

To compile the NYC Digital Health 100, NYCHBL used its dynamic database of digital health companies in the region and then invited companies to complete applications with quantitative and qualitative data to broaden the consideration set. A company qualified for consideration if it maintained headquarters or an office (over 10 people) in the New York region. Companies were judged on a number of factors, including but not limited to: strength of leadership, number of employees, funding (if known), revenue (if known), market fit, differentiated offerings, approach to diversity and equity, and community engagement.  

About Massive Bio 

Massive Bio’s mission is to provide access to clinical trials for every cancer patient regardless of the patient’s location and/or financial stability. Massive Bio is a proprietary patient recruitment and enrollment enablement solution for oncology clinical trials. Massive Bio provides unique tech enabled services and big data platform that addresses all points of friction in clinical trial enrollment. While improving cancer patients lives, Massive Bio serves over two dozen pharmaceutical companies, contract research organizations (CROs) and hospital networks. Massive Bio has been awarded an SBIR contract by the National Cancer Institute (NCI) to develop and characterize its Deep Learning Clinical Trial Matching System (DLCTMS), Contract No. 75N91020C00016. While improving cancer patient’s lives, Massive Bio also provides oncology dedicated data driven patient recruitment, site selection and artificial intelligence (AI) based trial prescreening services to its enterprise customers. Massive Bio was founded in 2015 and is headquartered in in NYC. Massive Bio has a 50 people team and founded by ex-M&A, clinical and technology executives.